GRM5 and fragile X syndrome: Since the limited necropsy findings may represent the changes in agonal and post-mortem periods, in vivo measurement of the expression of mGluR5s is needed, which may bring an initial insight into failed clinical trials that used investigational agents acting on mGluR5 in humans FXS.